Research programme: sustained-release therapeutics - Daewoong Pharmaceutical
Alternative Names: DWJ 1303; DWJ 1335; DWJ 1365Latest Information Update: 28 Feb 2019
At a glance
- Originator Daewoong Pharmaceutical
- Class Antidementias; Antipsychotics; Antiulcers
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dementia; Peptic ulcer; Psychotic disorders
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Dementia in South Korea (PO, Controlled release)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Peptic-ulcer in South Korea (PO, Controlled release)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Psychotic-disorders in South Korea (PO, Controlled release)